Abstract: An object of the present invention is to provide a method of treating thoracic cancer using a checkpoint inhibitor in combination with Ad-REIC/Dkk-3. The present invention is a pharmaceutical composition for treating thoracic cancer comprising REIC/Dkk-3 in combination with acheck point inhibitor and a method for treating thoracic cancer by administering Ad-REIC/Dkk-3 and a check point inhibitor to a thoracic cancer patient.
Abstract: This invention provides a therapeutic method for treatment of EGFR gene mutation-positive lung cancer using the REIC/Dkk-3 gene in combination with the EGFR tyrosine kinase inhibitor, the PD-1/-L1 immune checkpoint pathway inhibitor, and/or the molecular-targeted agent. This invention provides a therapeutic agent comprising, as an active ingredient, the REIC/Dkk-3 gene, which is used in combination with the EGFR tyrosine kinase inhibitor, the PD-1/-L1 immune checkpoint pathway inhibitor, and/or the molecular-targeted agent for treatment of EGFR gene mutation-positive lung cancer.
Abstract: An object of the present invention is to provide a method of treating cancer using a checkpoint inhibitor in combination with REIC/Dkk-3 gene. The present invention is a combination pharmaceutical kit for treating cancer comprising REIC/Dkk-3 in combination with a check point inhibitor and a method for treating cancer by administering REIC/Dkk-3 gene and a check point inhibitor to a cancer patient.
Abstract: This invention provides a method for treatment of hepatic cancer with the use of an anti-tumor agent in combination with the REIC/Dkk-3 gene. This invention also provides a therapeutic agent for treatment of hepatic cancer used in combination with an anti-tumor agent, which comprises, as an active ingredient, the REIC/Dkk-3 gene.
Type:
Application
Filed:
July 31, 2020
Publication date:
September 8, 2022
Applicants:
Momotaro-Gene Inc., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
Abstract: An object of the present invention is to provide a method of treating thoracic cancer using a checkpoint inhibitor in combination with Ad-REIC/Dkk-3. The present invention is a pharmaceutical composition for treating thoracic cancer comprising REIC/Dkk-3 in combination with a check point inhibitor and a method for treating thoracic cancer by administering Ad-REIC/Dkk-3 and a check point inhibitor to a thoracic cancer patient.
Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.
Type:
Grant
Filed:
September 27, 2016
Date of Patent:
September 22, 2020
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: An object of the present invention is to provide a method of treating cancer using a checkpoint inhibitor in combination with REIC/Dkk-3 gene. The present invention is a combination pharmaceutical kit for treating cancer comprising REIC/Dkk-3 in combination with a check point inhibitor and a method for treating cancer by administering REIC/Dkk-3 gene and a check point inhibitor to a cancer patient.
Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.
Type:
Application
Filed:
September 27, 2016
Publication date:
September 20, 2018
Applicants:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: An object of the present invention is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus to replicate specifically in a cancer cell and express REIC protein or REIC C domain protein, wherein the conditionally replicating adenovirus is obtained by inserting full-length REIC DNA or REIC C domain DNA into a conditionally replicating adenovirus comprising an ITR (inverted terminal repeat) sequence of an adenovirus type 5 genome and insertion of an HRE sequence, an hTERT promoter, a decorin-encoding DNA, and a DNA encoding a peptide comprising an RGD sequence.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
September 11, 2018
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc., Industry-University Cooperation Foundation Hanyang University
Inventors:
Hiromi Kumon, Yasutomo Nasu, Masami Watanabe, Chae Ok Yun
Abstract: An object of the present invention is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus to replicate specifically in a cancer cell and express REIC protein or REIC C domain protein, wherein the conditionally replicating adenovirus is obtained by inserting full-length REIC DNA or REIC C domain DNA into a conditionally replicating adenovirus comprising an ITR (inverted terminal repeat) sequence of an adenovirus type 5 genome and insertion of an HRE sequence, an hTERT promoter, a decorin-encoding DNA, and a DNA encoding a peptide comprising an RGD sequence.
Type:
Application
Filed:
May 26, 2015
Publication date:
July 20, 2017
Applicants:
National University Corporation Okayama University, Momotaro-Gene Inc., Industry-University Cooperation Foundation Hanyang University
Inventors:
Hiromi KUMON, Yasutomo NASU, Masami WATANABE, Chae Ok YUN
Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.
Type:
Grant
Filed:
January 15, 2016
Date of Patent:
May 9, 2017
Assignees:
NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, MOMOTARO-GENE INC.
Abstract: An object of the present invention is to provide a method for increasing the expression of foreign genes, in particular, using a promoter, an enhancer, and the like, and an expression cassette containing a promoter, an enhancer, and the like, by which gene expression can be increased. The purpose is achieved with the use of the gene expression cassette comprising a DNA construct containing a gene to be expressed and a poly A addition sequence that are located downstream of a 1st promoter, and further comprising an enhancer or a 2nd promoter ligated downstream of the DNA construct.
Type:
Grant
Filed:
November 19, 2010
Date of Patent:
November 15, 2016
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: An objective of the present invention is to provide an adenovirus vector expressing a REIC/Dkk-3 protein at a high level and containing a DNA construct for expression of REIC/Dkk-3 DNA, wherein the DNA construct is prepared by ligating, from the 5? terminal side, (i) a CMV promoter, (ii) REIC/Dkk-3 DNA, (iii) a polyA addition sequence, and (iv) enhancers prepared by linking an hTERT (Telomerase Reverse Transcriptase) enhancer, an SV40 enhancer, and a CMV enhancer in this order.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
December 29, 2015
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.
Abstract: According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.
Abstract: A method for potentiating the antitumor immunity in an animal by administering REIC/Dkk-3, or a therapeutic agent for malignant mesothelioma containing REIC/Dkk-3, or a vector containing the DNA as an active ingredient; wherein the DNA consists of the nucleotide sequence shown in SEQ ID NO: 1; or (b) a DNA hybridizing under stringent conditions to the DNA consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1 and encoding a protein having apoptosis-inducing activity and interleukin (IL-7) production-accelerating activity in cells.
Type:
Grant
Filed:
July 30, 2009
Date of Patent:
February 25, 2014
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.
Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.
Type:
Application
Filed:
July 1, 2011
Publication date:
October 10, 2013
Applicants:
Momotaro-Gene Inc., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
Abstract: According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.
Abstract: The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.